Highest-materiality recent filing
Rhythm Pharma Q2 revenue $71.3M; RM-718 shows -11.6% BMI reduction in HO
Q2 2026 IMCIVREE revenue $71.3M, up 19% sequentially; U.S. revenue $51.0M (+38% QoQ).
David W.J. McGirr elected with 53.2M votes for, 8.7M withheld; David P. Meeker with 60.0M for, 1.9M withheld.
Rhythm posts positive PWS Phase 2 data; MC4R agonist results at ENDO 2026
Interim Phase 2 PWS: 17 patients; mean BMI -3.06% at 6 months; 8/10 with moderate-severe hyperphagia improved ≥7 on HQ-CT.
Rhythm Q1 product revenue $60.1M; IMCIVREE HO launch >150 start forms; net loss $(0.83)/share
Q1 2026 net product revenue $60.1M (up 5% sequentially); U.S. revenue $36.9M, ex-U.S. $23.2M.
Rhythm Pharmaceuticals appoints Kim Popovits to Board; Ed Mathers resigns
Kimberly J. Popovits elected as Class II director effective April 1, 2026 until 2028 annual meeting.
Rhythm Pharma gets positive CHMP opinion to expand IMCIVREE label for acquired hypothalamic obesity
CHMP recommends expanding IMCIVREE (setmelanotide) marketing authorization to treat obesity/control hunger in patients >=4 years with acquired HO due to hypothalamic injury.
FDA approved IMCIVREE (setmelanotide) for acquired HO in adults and children 4+; first approved therapy for this indication.
Rhythm's Phase 3 EMANATE trial misses primary endpoints; post hoc signals in POMC/SRC1
Four substudies failed primary endpoint: placebo-adjusted BMI reductions of 4.3% (POMC/PCSK1), 3.6% (LEPR), 4.0% (SRC1), 1.7% (SH2B1); all p>0.05.
Rhythm reports additional positive Phase 3 TRANSCEND data for setmelanotide in hypothalamic obesity
Placebo-adjusted BMI reduction of 18.8% (N=142); primary endpoint met with -16.4% BMI change on setmelanotide vs +2.4% on placebo (p<0.0001).
Q4 2025 IMCIVREE revenue $57.3M, up 12% sequentially; full year revenue $194.8M vs $130.1M in 2024.
Rhythm Pharma Q4 2025 IMCIVREE revenue ~$57M (+11% QoQ); FY2025 ~$194M (+50% YoY)
Q4 2025 net product revenue ~$57M, up 11% sequentially from Q3 2025.
Dr. Camille Bedrosian resigns from Rhythm Pharmaceuticals board
Camille L. Bedrosian, M.D. resigned from the Board effective December 16, 2025.
Rhythm Pharma reports positive Phase 2 setmelanotide data in PWS; plans Phase 3
18 patients enrolled; 17 remain on therapy; safety consistent with known profile.
FDA extends review of Rhythm's setmelanotide sNDA to March 20, 2026
New PDUFA goal date March 20, 2026, extended 3 months from December 20, 2025.
Rhythm Q3 IMCIVREE revenue $51.3M; net loss -$0.82/sh; PDUFA Dec 20
Q3 2025 IMCIVREE revenue $51.3M (+6% seq, +54% YoY); US $38.2M (+19% seq).
Q2 net product revenue $48.5M, up 29% sequentially from Q1 2025; US revenue $32.0M (66% of total), up 31%.
Rhythm Pharmaceuticals raises $188.7M in public equity offering; underwriters exercise full option
Offering of 2,058,824 shares at $85.00 per share; underwriters exercised 30-day option for 308,823 additional shares in full.
Rhythm Pharma's bivamelagon Phase 2 meets endpoints: -9.3% BMI reduction at 14 weeks
BMI reduction -9.3% (600mg, p=0.0004) and -7.7% (400mg, p=0.0002) vs 2.2% increase on placebo.
Rhythm stockholders elect two Class II directors, approve officer exculpation amendment
Jennifer Good (55.6M votes for) and Edward T. Mathers (35.2M for) elected as Class II directors.
Rhythm Q1 product rev $37.7M; Phase 3 HO trial meets endpoint with -19.8% BMI reduction
Net product revenue $37.7M, up from $26.0M YoY; U.S. $24.5M, ex-U.S. $13.2M.
Mean BMI change of -16.5% on setmelanotide vs +3.3% for placebo at 52 weeks (p<0.0001); 80% achieved ≥5% BMI reduction.
Rhythm terminates RareStone license for IMCIVREE in China; reacquires rights for $6.3M
Termination of 2021 Exclusive License and Share Purchase agreements with RareStone Group Ltd.
Rhythm Pharmaceuticals sets June 24, 2025 annual meeting; deadline for proposals March 26
Annual meeting scheduled for June 24, 2025.
Rhythm Q4 2024 IMCIVREE revenue $41.8M; cash runway extended to 2027
Q4 2024 IMCIVREE net revenue $41.8M (+26% sequential, +73% YoY); FY2024 total $130.1M.
Preliminary Q4 2024 IMCIVREE net revenues of ~$42M, up 26% sequentially; full year ~$130M vs $77.4M in 2023.
Rhythm Pharma Q3 revenue $33.3M (+14% seq); FDA Priority Review for label expansion to age 2
IMCIVREE net revenue $33.3M (Q3 2024), up 48% YoY from $22.5M; US sales $23.3M (+8% seq), ex-US $10.0M (+35% seq).
Rhythm Pharma shareholders elect three directors, approve equity plan at annual meeting
Elected Class I directors: Stuart Arbuckle (45.6M for), Christophe Jean (45.0M), Lynn Tetrault (45.5M).
Rhythm Pharma Q2 2024 revenue $29.1M, up 52% YoY; net loss narrows to $33.6M
Net product revenue $29.1M vs $19.2M in Q2 2023; 74% generated in United States.
Rhythm Pharmaceuticals files prospectus for resale of 3.1M shares by selling stockholders
Registration covers up to 3,124,995 common shares held by certain stockholders to satisfy registration rights.
Rhythm Pharmaceuticals postpones 2024 annual meeting to Sept 18 due to record date error
Annual meeting postponed from June 18 to September 18, 2024; new record date July 24, 2024.
Rhythm Pharma Q1 net revenue $26.0M (+126% YoY); net loss $141.4M on $92.4M LB54640 charge
Net product revenue $26.0M (Q1 2023: $11.5M); 74% from U.S. sales.
Rhythm Pharmaceuticals closes $150M Series A Convertible Preferred issuance to Perceptive affiliates
Closed on April 15, 2024; issued 150,000 shares at $1,000 each for aggregate $150,000,000.
Rhythm Pharma raises $150M in convertible preferred stock; conversion at $48 (19% premium)
$150M gross proceeds from sale of Series A Convertible Preferred Stock to Perceptive and other existing shareholders.
Rhythm Pharmaceuticals amends sales agreement to allow up to $200M in at-the-market stock offerings
Amendment increases ATM offering limit from $100M to $200M, excluding $50M already sold.
Rhythm Pharma Q4 IMCIVREE rev $24.2M; reports material weakness in IT controls
Q4 2023 net product revenue $24.2M (FY2023 $77.4M) vs $8.8M Q4 2022; net loss $41.6M ($0.70/share).
Rhythm Pharmaceuticals licenses LB54640 from LG Chem for $60M upfront plus $40M deferred
License deal: $40M cash + $20M stock upfront; additional $40M cash due 18 months after effective date.
Rhythm Pharmaceuticals posts updated corporate slide presentation
Posted a corporate slide presentation with recent business and financial updates on IR website.
Amended and restated bylaws adopted by Board on Dec 14, 2023, effective same day.
Rhythm Pharma reports positive Phase 3 setmelanotide data in young children; files for EU approval
Phase 3 pediatrics trial: 83.3% (10/12) achieved BMI-Z score reduction ≥0.2 at 52 weeks; mean BMI reduction 18.4%.
Rhythm Pharma Q3 IMCIVREE revenue $22.5M, net loss $44.2M; Phase 3 hypothalamic obesity on track
Q3 2023 net product revenue from IMCIVREE $22.5M vs $4.3M in Q3 2022; 80% from U.S.
Rhythm Pharmaceuticals raises $50M via ATM equity offering of 2M shares
Sold ~2.019M shares of common stock from Aug 10-21, 2023, for gross proceeds of ~$50M.
Rhythm Pharma terminates CAO, appoints Christopher German as principal accounting officer
William T. Roberts terminated as CAO effective Aug 11, 2023; no reason stated.
Rhythm Pharma amends exec comp; CEO base $717k, severance enhanced for change of control
CEO Meeker: base salary $717,254, bonus target 65%, severance 12 months (18 months +150% bonus on change in control).
Rhythm Q2 2023 revenue $19.2M; BBS prescriptions top 425; eligible for $25M milestone payment
Q2 2023 net product revenue $19.2M (vs $2.3M Q2 2022); net loss $46.7M ($0.82/share).
Rhythm Pharma annual meeting: all proposals approved by stockholders
49,290,096 shares (~86.7%) present at June 21, 2023 meeting.
Rhythm Pharma Q1 revenue $11.5M, net loss $52.2M; BBS prescriptions over 300 since launch
Net product revenue $11.5M in Q1 2023 vs $1.5M YoY; net loss $52.2M ($0.92/sh) vs $52.8M ($1.05/sh).
Rhythm discloses $3.4M in SVB deposits, 1.1% of total cash, after SVB closure
Approximately $3.4M held in deposit accounts at Silicon Valley Bank, representing 1.1% of total cash and equivalents.
Rhythm Pharma Q4 2022 product revenue $8.8M, net loss $42.5M; BBS launch >200 scripts
Product revenue $8.8M Q4 2022, $16.9M FY; net loss $42.5M ($0.75/sh) Q4, $181.1M ($3.47/sh) FY.
Rhythm Pharmaceuticals furnishes corporate slide deck; no material changes disclosed
Slide deck posted to investors section of company website on January 9, 2023.
Rhythm Q3 2022: IMCIVREE revenue $4.3M; net loss $40.9M; cash $347.8M
Product revenue $4.3M vs $1.0M YoY; net loss $40.9M ($0.79/share) vs $35.1M ($0.70).
On August 8, 2023, the Board of Directors of the Company designated Christopher German, the Company’s Executive Director, Corporate Controller, as principal accounting officer, effective on the Effective Date.
On August 4, 2023, Rhythm Pharmaceuticals, Inc. (the “Company”) notified William T. Roberts, the Company’s Chief Accounting Officer, of the termination of Mr. Roberts’ employment with the Company, to be effective on August 11, 2023
The Board has appointed Linda Shapiro Manning, M.D., Ph.D., currently Senior Vice President, Clinical of the Company, to succeed Dr. Stewart as Chief Medical Officer as of the Effective Date.
On August 31, 2021, Murray Stewart, D.M., F.R.C.P. notified Rhythm Pharmaceuticals, Inc. (the “Company”) of his resignation as Chief Medical Officer, effective as of September 10, 2021
Max materiality 0.90 · Median 0.70 · Most common event other_material